Quantum-Si Inc stock (US7491641091): valuation metrics under focus after rising short interest

Quantum-Si shares on Nasdaq remain volatile as short interest climbed in mid-May 2026, putting the United States-based proteomics player’s valuation metrics back in focus for investors tracking early-stage life science tools names.

Quantum-Si, listed on Nasdaq under the ticker QSI in the United States, continues to see active trading, with investors monitoring the stock’s valuation as short interest increased in May 2026 according to market data providers as of 05/15/2026.

Based in the United States and trading in USD on Nasdaq, the company sits within the life science tools and measurement technology space, and the latest short interest statistics highlight the market’s divided view on the pace at which the business can scale its proteomics platform.

MarketBeat data show that as of 05/15/2026, approximately 23.25 million Quantum-Si shares were sold short, corresponding to around 13.7% of the public float, with a short interest ratio of 3.9 days based on an average daily trading volume of about 6.09 million shares as reported on that date.

This means that, at mid-May 2026 trading volumes, it would take almost four full trading days for short sellers to cover their positions if they chose to buy back stock in the open market, a metric investors in the United States often use to gauge potential pressure points in volatile small-cap names.

MarketBeat also notes that the short interest figure of 23,252,541 shares as of 05/15/2026 represented an increase of 1.2% compared with the previous reading of 22,967,445 shares earlier in the month, underlining that bearish positioning ticked higher rather than easing over that period.

For a relatively young company positioned in the proteomics and semiconductor-based sequencing field, such a short interest profile can translate into sharper price swings on Nasdaq, especially when news catalysts around product adoption, financing, or regulatory milestones emerge and prompt rapid shifts in sentiment.

At the same time, the days-to-cover ratio below five days still suggests that, while elevated, the level of short positioning is not extreme compared with some other early-stage growth stocks, which can show double-digit days-to-cover values in periods of stress.

In the home market context of the United States, Quantum-Si trades alongside a broader cohort of life science tools and diagnostics companies on Nasdaq, meaning its valuation is frequently assessed against peers with different maturity levels, revenue bases, and profitability profiles.

For German-speaking investors, the stock is also available via off-exchange platforms such as Tradegate in euros, though liquidity and spreads there typically differ from the primary United States listing, and price discovery continues to be driven predominantly by Nasdaq trading in USD.

Investors following the stock on 05/29/2026 are therefore weighing the mid-May short interest data together with broader market conditions for high-beta growth names on US exchanges, where changes in interest rates and risk appetite have had a pronounced impact on valuation multiples across the sector.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: QSI
• Sector/industry: Life science tools and proteomics technology
• Headquarters/country: Branford, United States
• Core markets: United States, Europe, selected Asia-Pacific research hubs
• Key revenue drivers: Proteomic sequencing instruments, consumables, and related software
• Home exchange/listing venue: Nasdaq (QSI)
• Trading currency: USD

Quantum-Si Inc: core business model

Quantum-Si focuses on developing semiconductor-based proteomic sequencing systems that pair instruments with recurring consumables and software to help research and biopharma customers analyze proteins with higher throughput.

Valuation metrics and multiples for Quantum-Si Inc

When looking at Quantum-Si from a valuation perspective as of late May 2026, investors need to account for the company’s early-stage profile, meaning traditional metrics such as price-to-earnings often offer limited insight because earnings remain negative or minimal and the focus is instead on cash runway, operating loss trends, and revenue growth trajectory over coming years.

In such cases, market participants in the United States commonly look at indicators like price-to-sales where verifiable revenue data are available, enterprise value compared with the company’s cash position, and implied valuation versus the size of the targeted proteomics tools and consumables market, while also cross-checking short interest levels such as the 13.7% figure reported for 05/15/2026 as a barometer of how skeptical or constructive other traders are about the stock’s longer-term upside.

Conclusion

Quantum-Si’s Nasdaq-listed shares are currently framed by a mid-May 2026 short interest level of 13.7% of the float and a days-to-cover ratio just under four days, signaling that a notable segment of the market is positioning for further downside or volatility.

At the same time, valuation work for this United States life science tools stock leans more heavily on metrics such as cash resources, revenue growth potential, and enterprise value versus the size of the proteomics opportunity rather than on conventional earnings multiples, given the company’s development stage.

How these valuation considerations interact with evolving short interest data and upcoming operational milestones will likely shape trading dynamics for Quantum-Si on Nasdaq over the coming months.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.